PMID- 22589375
OWN - NLM
STAT- MEDLINE
DCOM- 20130701
LR  - 20151119
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
VI  - 72
IP  - 5
DP  - 2013 May
TI  - Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in 
      patients with systemic lupus erythematosus: a case-control study.
PG  - 659-64
LID - 10.1136/annrheumdis-2012-201393 [doi]
AB  - OBJECTIVES: To evaluate the immunogenicity and safety of GARDASIL, a quadrivalent 
      human papillomavirus (HPV) vaccine, in patients with systemic lupus erythematosus 
      (SLE). METHODS: Women with SLE aged 18-35 years who had stable disease were 
      recruited to receive GARDASIL vaccination and an equal number of age-matched 
      healthy women were also vaccinated. Seroconversion rates of antibodies to HPV 
      serotypes 6, 11, 16 and 18 at months 7 and 12 and adverse events (AEs) were 
      compared between patients and controls. The rate of disease flares in SLE 
      participants was compared with matched SLE controls. RESULTS: 50 patients with 
      SLE and 50 healthy controls were studied. The mean age and disease duration of 
      the patients was 25.8+/-3.9 years and 6.6+/-4.5 years, respectively. At month 12 the 
      seroconversion rates of anti-HPV serotypes 6, 11, 16 and 18 in patients and 
      controls were 82%, 89%, 95%, 76% and 98%, 98%, 98%, 80%, respectively. In 
      patients with SLE there were no significant changes in the titres of anti-dsDNA, 
      complements, anti-C1q and SLE Disease Activity Index scores from baseline to 
      months 2, 7 and 12. There was one mild/moderate SLE flare at months 0-2, two 
      mild/moderate flares at months 3-6 and six mild/moderate and two severe flares at 
      months 7-12. Disease flares in patients with SLE occurred at a similar frequency 
      to that of 50 matched SLE controls (0.22/patient/year vs 0.20/patient/year, 
      p=0.81). Injection site reaction was the commonest AE (5%), and the incidence of 
      AEs was comparable between patients with SLE and controls. CONCLUSIONS: The 
      quadrivalent HPV vaccine is well tolerated and reasonably effective in patients 
      with stable SLE and does not induce an increase in lupus activity or flares.
FAU - Mok, Chi Chiu
AU  - Mok CC
AD  - Department of Medicine, Tuen Mun and Pok Oi Hospital, New Territories, Hong Kong, 
      SAR China. ccmok2005@yahoo.com
FAU - Ho, Ling Yin
AU  - Ho LY
FAU - Fong, Lai Shan
AU  - Fong LS
FAU - To, Chi Hung
AU  - To CH
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120515
PL  - England
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
RN  - 0 (Antibodies, Viral)
RN  - 0 (Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18)
RN  - 0 (Papillomavirus Vaccines)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Alphapapillomavirus/*immunology
MH  - Antibodies, Viral/blood
MH  - Case-Control Studies
MH  - Disease Progression
MH  - Female
MH  - Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
MH  - Humans
MH  - Immunocompromised Host/*immunology
MH  - Lupus Erythematosus, Systemic/*immunology
MH  - Papillomavirus Infections/immunology/*prevention & control
MH  - Papillomavirus Vaccines/*administration & dosage/adverse effects/*immunology
MH  - Prospective Studies
MH  - Young Adult
EDAT- 2012/05/17 06:00
MHDA- 2013/07/03 06:00
CRDT- 2012/05/17 06:00
PHST- 2012/05/17 06:00 [entrez]
PHST- 2012/05/17 06:00 [pubmed]
PHST- 2013/07/03 06:00 [medline]
AID - annrheumdis-2012-201393 [pii]
AID - 10.1136/annrheumdis-2012-201393 [doi]
PST - ppublish
SO  - Ann Rheum Dis. 2013 May;72(5):659-64. doi: 10.1136/annrheumdis-2012-201393. Epub 
      2012 May 15.